Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

NCT03836157 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT03836157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03836157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2019
Completion date
May 31, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial cancer, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma